Esperion to Present at Key Healthcare Event
Esperion (NASDAQ: ESPR) is gearing up for an important presentation at the upcoming Piper Sandler 37th Annual Healthcare Conference. This notable event is scheduled to take place in New York, providing Esperion with an excellent platform to share insights and advancements in their innovative therapies for cardiovascular health.
Details of the Conference Presentation
The presentation will occur on December 3, during the afternoon session. Interested parties can access the live webcast through the investor section of the Esperion website. There, viewers can also find additional information about Esperion's ongoing projects and strategic goals.
What to Expect from Esperion
As a leader in the biopharmaceutical sector, Esperion is focused on addressing critical health challenges, particularly in managing low-density lipoprotein cholesterol (LDL-C) levels. Their oral therapies represent a significant advancement over traditional statin medications, providing a more convenient daily option for patients.
Innovations in Cardiovascular Therapies
Esperion's commitment to innovation is evident in their robust pipeline of treatments. The company is well-known for developing the only FDA-approved once-daily oral medications designed specifically for patients susceptible to cardiovascular diseases. These approaches stem from thorough clinical research, including the impactful CLEAR Cardiovascular Outcomes Trial, which involved nearly 14,000 patients.
Future Direction and Research Efforts
Beyond their current offerings, Esperion is progressing towards the next generation of cardiovascular treatments. They are concentrating on ATP citrate lyase inhibitors, a groundbreaking category of drugs that promise to provide potent and specific outcomes for patients managing their cholesterol levels.
Building Partnerships and Expanding Global Reach
Esperion is evolving as a key player in the global biopharmaceutical market through an emphasis on strategic partnerships and collaborations. Their dedication to advancing both commercial strategies and research endeavors ensures they remain at the forefront of healthcare innovation.
Company Information Overview
Founded with a focus on unmet medical needs, Esperion Therapeutics aims to transform cardiovascular care for patients. By blending scientific expertise with patient-centered care, Esperion is poised for enduring success as a commercial stage company in the biopharmaceutical landscape.
Esperion Contact Information
For investor inquiries, please contact:
Alina Venezia
investorrelations@esperion.com
(734) 887-3903
For media inquiries, contact:
Tiffany Aldrich
corporateteam@esperion.com
(616) 443-8438
Frequently Asked Questions
What is the main focus of Esperion at the conference?
Esperion will showcase their advancements in cardiovascular therapies, highlighting their significant contributions to patient care.
Where can I access the live presentation?
The live webcast will be available on Esperion's investor website during the scheduled presentation time.
What types of medications does Esperion focus on?
Esperion specializes in developing oral medications aimed at managing low-density lipoprotein cholesterol levels for cardiovascular patients.
How large was the CLEAR Cardiovascular Outcomes Trial?
This pivotal trial involved approximately 14,000 patients, underscoring the effectiveness of Esperion’s therapies.
Who can I contact for more information about Esperion?
For investor or media inquiries, you can reach out to Alina Venezia or Tiffany Aldrich through the provided email addresses.
